Significant decline in investments in Israeli life sciences companies in 2025
A newly published report presents a complex picture of the Health-Tech industry in Israel. While 2024 saw an encouraging recovery in investments, 2025 brings new economic challenges for companies in the sector.
According to the data, there has been a sharp 40% decline in the volume of investments in Israeli life sciences companies compared to the previous year. This is a significant shift that concerns those in the industry, as it is one of the most central and innovative sectors in the Israeli economy.
In addition to the overall decline in investments, the report points to a continuing trend of a decrease in the average amount of each deal. This means that medical and technology start-ups are finding it harder to raise large sums as they did in the past, which could affect the pace of development for new products and technologies.
Despite the challenging data regarding capital raising, the report notes that the exports of life sciences companies remain stable. This fact indicates that Israeli products and services still enjoy demand in international markets, despite the difficulties in raising funds in the local market.
Investors and market analysts will continue to monitor the trends closely in the coming months. It remains to be seen whether this is a temporary change or a prolonged period of slowdown that will require companies to adapt their business models to the new economic reality.